iShares Russell 2000 ETF (IWM)

For the fourth quarter, Zevra announced net revenue of $34.1 million, exceeding an analyst estimate of $28.05 million.

The company announced its decision following a meeting with the U.S. Food and Drug Administration.

ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease.

In the first quarter of 2026, the financial markets have undergone a definitive "regime change" that many analysts are calling the "Great Convergence." After years of an increasingly narrow market led by a handful of mega-cap technology giants, the tide has finally turned. The iShares Russell 2000 ETF (NYSE: IWM)

The sharp rally has piqued retail traders’ interest in the conservative-leaning news network.

Rosenblatt lowered the firm's price target on Webull to $12 from $15 and kept a ‘Buy’ rating on the shares, per TheFly.

As per Dorsey, any growth at Serve Robotics will fall short of investor expectations for multiple reasons.

The company posted net income per ordinary share of $0.01 that was below Wall Street estimates of $0.05 per share as per data from Fiscal.ai.

According to Vanda, the FDA has not granted such a hearing in the context of drug approvals for potentially over 40 years.

Compare how cost, sector focus, and risk profiles set IVV and IWM apart for investors seeking different equity exposures.

Ziff Davis said the sale to Accenture is expected to close in the coming months.

Expense ratios, sector weights, and portfolio breadth set these two ETFs apart.

The company said that Jose Luis Crespo will assume the role of Chief Executive Officer effective March 2, 2026.

The company announced that the U.S. FDA lifted a clinical hold on its Phase 3 trial of ATTR-CM treatment drug.

The company said that its fourth quarter 2025 net income was $40 million, or $0.23 per share, compared to a net loss of $68 million, or $0.40 per share in 2024.

SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy.

The plant-based meat company added four flavors to its beverage lineup on Thursday.

H.C. Wainwright sees risks associated with Mara's pronounced pivot to AI and hyperscale data centers.

The company reported a 34% jump in fourth-quarter revenue to $134.3 million, beating Wall Street’s estimates of $128.2 million, according to Fiscal.ai data.